Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01890967 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 527
- Enrollment target
NCT01890967: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT01890967 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 527 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (296% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01890967, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 527 participants
- Enrollment target
Study Summary
This study is designed to define the amount and duration of cholesterol lowering and to assess the safety and tolerability of different dose regimens of LY3015014 in participants with high cholesterol. The study will also investigate how the body processes the drug and how the drug affects the body. Participants will remain on a stable diet and will continue taking cholesterol-lowering medications (statins with or without ezetimibe). After signing the informed consent document, the participant will complete a screening/run-in period that will last at most 8 weeks. Then, the treatment period will last approximately 16 weeks. After the treatment period, the participants will complete a follow-up period lasting approximately 8 weeks for a total study duration ranging from approximately 25 to 32 weeks.
Primary Outcome
Least square (LS) Means was calculated using analysis of covariance (ANCOVA) adjusted for disease classification, statin dose, baseline LDL-C measurement. Percent change from baseline response is the dependent variable.
Interventions
- DRUG Placebo
- DRUG Ezetimibe
- DRUG Statin
- DRUG LY3015014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT01890967 record still lists
NCT01890967 is an interventional study that assigns participants to a tested intervention. The registered 527 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (296% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01890967 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01890967 about?
NCT01890967 is a clinical study titled "A Study of LY3015014 in Participants With High Cholesterol". This study is designed to define the amount and duration of cholesterol lowering and to assess the safety and tolerability of different dose regimens of LY3015014 in participants with high cholesterol. The study will also investigate how the body processes the drug and how the drug affects the body....
What is the current status of trial NCT01890967?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 527 participants. The study started on 2013-06. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01890967?
The interventions under investigation include: Placebo (DRUG), Ezetimibe (DRUG), Statin (DRUG), LY3015014 (DRUG).
Who is sponsoring clinical trial NCT01890967?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01890967's enrollment target sits among peer trials
527 65th of 2000 higher than 1,936 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia